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Context: Little is known about testosterone (T) levels and their
determinants in women of late postmenopausal age.
Objective: We describe levels of total and free T and selected factors
that influence these levels in a random sample of older women.
Design: Levels of serum total T and free T by microdialysis were
measured using ultrasensitive assays in 347 community-dwelling
women aged 65–98 yr enrolled in the Cardiovascular Health Study.
Cross-sectional analyses were performed to define factors associated
with total and free T levels.
Results: In adjusted models: 1) total T levels declined with age until
80, whereas free T levels did not vary by age; 2) women with bilateral
oophorectomy had 23% lower total T and 16% lower free T levels than
those with at least one intact ovary; 3) oral estrogen users had total
and free T levels that were 47% lower than never users; 4) obese
women had 47% higher total T and 20% higher free T levels, and
overweight women had 24% higher total T and 14% higher free T
levels, than normal weight women; and 5) free T levels were 51%
higher in black women. Corticosteroid users had 75% lower total T
and 43% lower free T levels than nonusers.
Conclusions: Bilateral oophorectomy, estrogen use, corticosteroid
use, and low body mass index are independent risk factors for lower
T levels in women aged 65 yr and over. Although highly prevalent in
women of this age, the physiological significance of low T levels in late
postmenopausal women requires further investigation. (J Clin En-
docrinol Metab 92: 509–516, 2007)
THE ROLE OF androgens in women is an area of mount-ing scientific and public interest. A female androgen
insufficiency syndrome has been suggested, the effects of
which include increased fatigue; diminished sense of well-
being; and decreased libido, bone mass, muscle strength, and
memory (1). Specific risk factors for lower testosterone (T)
levels in younger women include bilateral oophorectomy,
estrogen use, corticosteroid use, adrenal or pituitary disease,
and HIV infection (2). However, few data are available re-
garding T levels in women over 65 yr old, despite continued
production of androgens by the postmenopausal ovary in a
gonadotropin-driven fashion, and whether the same deter-
minants of T levels in younger women are relevant in later
life (3, 4).
One explanation for the paucity of valid studies is the
difficulty in assessing the very low T levels present in this
population (5). Many published studies have used T assays
with low sensitivity and poor reliability or included small
numbers of women over 65 yr (6, 7). No prior studies have
measured free T by dialysis in women over 65 yr. In 684
women aged 50–89 yr enrolled in the Rancho Bernardo
Study, levels of total and bioavailable T were 40% lower in
women with bilateral oophorectomy than in those with intact
ovaries (8), a finding recently confirmed in another cross-
sectional study with women up to age 75 yr (9). To our
knowledge, no studies have examined the simultaneous im-
pact of oophorectomy, estrogen use, and other relevant fac-
tors on T levels in late postmenopausal women. This infor-
mation is essential if older women are affected by low
androgen levels, for identification and avoidance of predis-
posing risk factors, and consideration of physiological tes-
tosterone replacement (10). Using highly sensitive assays, we
aimed to describe levels of total T and free T by dialysis,
selected factors that influence them, and the relationship
between total and free T levels in late postmenopausal
women. We hypothesized that the same factors that affect T




The Cardiovascular Health Study (CHS) is a population-based, lon-
gitudinal study of risk factors for developing cardiovascular diseases in
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5888 adults aged 65 yr and older (11). Enrollment of an original cohort
of 5201 adults occurred between May 1989 and June 1990, and an ad-
ditional cohort of 687 predominantly African-Americans enrolled in
1992–1993. Eligible individuals were identified from an age- and gender-
stratified random sample of the Medicare eligibility rosters in four U.S.
communities: Washington County, Maryland; Pittsburgh (Allegheny
County), Pennsylvania; Sacramento County, California; and Forsyth
County, North Carolina. To be eligible, individuals had to be noninsti-
tutionalized, expecting to remain in the area for the following 3 yr, not
under active cancer treatment, not wheelchair bound in the home, not
requiring a proxy respondent at entry, and capable of providing consent.
Household members of the sampled individual were recruited, if eli-
gible. The institutional review boards of all four sites and the coordi-
nating center at the University of Washington in Seattle approved the
study, and all participants gave informed consent.
Random selection of the participants for our analyses was performed
by the CHS coordinating center, using a computer program to generate
a random list of identification numbers from all women with blood
samples collected at the 1992–1993 visit. The first 350 identification
numbers from that list were sent to the CHS Central Blood Analysis
Laboratory for sample pulling; 348 had adequate sample for analysis and
were included in our subcohort. The 1992–1993 visit included a detailed
medical history, physical examination, and assessment of health status.
Blood was drawn in the morning after a 12-h fast and serum was frozen
in 70 C freezers for future investigations (12). Women in our subcohort
were slightly older than in the CHS cohort but exhibited the same
distribution of race, body mass index (BMI), estrogen use, and repro-
ductive history.
Assessment of biochemical measures
Total T concentrations were measured by RIA using iodinated T as
a tracer (13), which was validated against liquid chromatography-
tandem mass spectrometry (LC-MS/MS), as described previously (14).
These measurements demonstrated a correlation of 0.997 between the
RIA and LC-MS/MS measurements (14). The sensitivity, defined as
hormone concentration corresponding to 90% B/B0 [percent bound in
presence (B) and absence (B0) of analyte] point, was 0.22 ng/dl (0.008
nmol/liter). The intra- and interassay coefficients of variation were 8.2
and 13.2%, respectively.
Free T concentrations were measured by a sensitive equilibrium di-
alysis assay (13), optimized to precisely and accurately measure low
concentrations. The sensitivity of this assay is 0.6 pg/ml (2.0 pmol/liter);
the intra- and interassay coefficients of variation were 4.2 and 12.3%,
respectively.
The normative range for total and free T levels in different phases of
the menstrual cycle, established in healthy, menstruating women, has
been published using these assays (13).
Assessment of covariates
Sociodemographic characteristics included age, race, education,
smoking status, alcohol use, age at menopause, prior hysterectomy, age
at hysterectomy, prior oophorectomy, age at oophorectomy, and num-
ber of ovaries removed. BMI (kilograms per square meter), computed
from objective measures, was categorized as less than 18.5, 18.5–24.9,
25–29.9, or 30 or greater. Medication use was determined from exam-
ination of medication bottles at the study visit.
Statistical analysis
Total and free T levels were summarized across subject characteristics
using standard descriptive statistics. T levels were graphed against age;
a lowess curve was applied to assess for a linear relationship. Log-
transformed total vs. free T levels were plotted and Pearson’s correlation
coefficient was used to test for statistical significance. Paired t tests and
one-way ANOVAs were performed to determine factors associated with
the log-transformed total and free T levels. Factors found statistically
significant at a P  0.1 level, based on two-sided tests, were included in
multivariable linear regression models. Estimates from these models
were back transformed for interpretation on the original T scales, re-
sulting in multiplicative rather than additive effects. For example, a
variable with a backtransformed estimate of 2 for category X implies that
a woman in category X has on average double the T levels of a woman
in the reference category for that variable. Due to collinearity between
race and educational status in our study population, only race was
included in the final multivariate models.
Of 348 women in the original sample, one extreme outlier was ex-
cluded from the total T and four from the free T analyses. Two additional
women were excluded from the free T analyses due to insufficient
serum. Nine women taking oral corticosteroids were excluded from the
regression models, due to their small number and extreme difference in
values from the remainder of the sample.
Results
Demographic and reproductive characteristics
The 347 women ranged in age from 65 to 98 yr, with a mean
age of 74 yr. Seventeen percent were black and 85% had at
least a high school education (Table 1). The mean BMI in our
study cohort was 26.8 kg/m2. The majority (88%) had been
pregnant at least once (Table 2). Overall, 43% of the women
had undergone a hysterectomy and 16% reported bilateral
oophorectomy. Sixty-three percent reported natural meno-
pause, whereas 33% had undergone premenopausal hyster-
ectomy; this information was unavailable in 4%. Nineteen
percent were current oral estrogen users, and 27% had taken
estrogen in the past. Nine women (3%) were taking oral
corticosteroids.
Total and free testosterone levels
Serum total T levels ranged from 1 to 133 ng/dl (0.03 to
4.61 nmol/liter), with a mean of 20  19 ng/dl (0.69  0.66
nmol/liter) and a median of 15 ng/dl (0.52 nmol/liter). Se-
rum free T levels ranged from 0.3 to 20.6 pg/ml (1.1 to 71.5
pmol/liter), with a mean of 2.8  2.5 pg/ml (9.7  8.7
pmol/liter) and a median of 2.0 pg/ml (6.9 pmol/liter). In a
reference population of 34 healthy premenopausal women
using the same assay (13), performed in the same laboratory,
the range for total T was 11.5 to 77.8 ng/dl (0.40 to 2.70
nmol/liter), the mean peak (preovulation) total T was 44
ng/dl (1.53 nmol/liter) and the mean trough (early follicular)
total T was 30 ng/dl (1.04 nmol/liter). The range for free T
in these premenopausal women was 1.2 to 7.6 pg/ml (4.1 to
24.2 pmol/liter), the mean peak free T was 4.2 pg/ml (14.6
pmol/liter) and the mean trough free T was 3.2 pg/ml (11.1
pmol/liter).
Comparisons of total and free testosterone levels
Total and free T levels were highly correlated with each
other (r  0.62 for total vs. free testosterone, P  0.001). The
correlation between total and free T levels was poorest at the
lowest levels of total and free T, as shown in Fig. 1. After
removing the 60 women with total T levels 5 ng/dl or less,
the correlation improved slightly, to 0.69 (P  0.001).
Predictors of total and free testosterone levels:
bivariate models
Total T levels appeared to have a nonlinear relationship
with age, whereas there was no apparent relationship be-
tween free T and age (Fig. 2). In bivariate models, the lowest
total T levels were found in subjects 75–79 yr old, whereas
free T levels did not differ significantly by age group (Table
1). Otherwise, the predictors of total and free T levels were
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identical (Tables 1 and 2). White race, greater education,
lower BMI, bilateral oophorectomy, present or past use of
estrogens, and oral corticosteroid use were each individually
associated with lower total and free T levels (Tables 1 and 2).
Total and free T levels did not vary significantly by smoking
status or alcohol intake.
Several reproductive variables were evaluated for poten-
tial influence on total and free T levels (Table 2). Total and
free T levels were unrelated to prior pregnancy. The meno-
pause type (natural vs. surgical) did not affect T levels, unless
both ovaries were removed at the time of surgery. Total and
free T levels were similar between women who underwent
natural menopause and women who had a hysterectomy
with ovaries left intact. Total and free T levels were signif-
icantly lower in women who had both ovaries removed,
whether before or after their natural menopause, compared
with women who never had ovaries removed, had one ovary
removed, or who did not know their ovarian status.
Only nine women were taking oral corticosteroids in our
study group. However, corticosteroid use had a greater effect
on T levels than any of the assessed factors, with mean total
T levels 75% lower than in noncorticosteroid users (Table 2).
Because of the extreme differences in their T values, women
who were taking oral corticosteroids were excluded from all
multivariate analyses.
Predictors of total and free testosterone levels:
multivariate models
In models including age, race, BMI, number of ovaries
removed, and estrogen use, age was a predictor of total T
levels. Women over age 70 yr had lower total T levels than
those 65–69 yr (Table 3). Race was not a statistically signif-
icant determinant of total T levels after adjusting for the other
covariates. Total T levels were linearly associated with BMI
(P  0.005). Obese women (BMI  30 kg/m2) had 47% higher
total T levels (P  0.003) and overweight women (BMI 25–
29.9 kg/m2) 24% higher total T levels (P  0.07) than women
with a BMI between 19 and 25 kg/m2. Women taking oral
estrogens at the time of the study visit had total T levels 47%
lower than those who had never taken estrogen (P  0.001).
Participants who were past users had intermediate levels
between current and never users, with levels 16% lower than
those who had never taken estrogen, although this was not
statistically significant. Women with bilateral oophorectomy
had 23% lower total T levels than those with at least one intact
ovary (P  0.05).
In multivariate models, age was not a predictor of free T
levels, with similar estimates across all age groups (Table 4).
Black women had 51% higher free T levels than white women
(P  0.0001). Free T levels were linearly associated with BMI.
Obese women (BMI  30 kg/m2) had 20% higher free T levels
(P  0.05) and overweight women (BMI 25–29.9 kg/m2) had
14% higher free T levels (P  0.11) than women with a BMI
between 19 and 25 kg/m2. Current and past estrogen use
were each associated with lower free T levels, with 47% lower
levels in current users (P  0.01) and 22% lower in past users
(P  0.03). Women with bilateral oophorectomy had 16%
lower free T levels than women with at least one intact ovary
(P  0.06). In models replacing age with years since meno-
TABLE 1. Total and free T levels within demographic categories
Variable Sample(%)
Total T, mean  SD
(ng/dl) (n  347)
Free T, mean  SD
(pg/ml) (n  342)
Age (yr)
65–69 15 22  15a 2.7  1.9
70–74 43 20  20 2.8  2.4
75–79 26 17  18 3.1  3.2
80 16 23  22 2.8  2.1
Race
White 83 19  19a 2.6  2.1b
Black 17 25  20 4.2  3.7
Education
Less than high school 15 25  23a 3.7  3.6a
High school graduate 40 20  17 2.8  2.1
Some college 45 18  18 2.6  2.4
BMI (kg/m2)
18.5 5 13  13b 1.7  0.5a
18.5–24.9 35 16  19 2.4  1.8
25–29.9 35 20  17 2.9  2.6
30.0 25 26  22 3.4  3.2
Smoking
Never 49 21  21 2.9  2.5
Former 40 19  19 2.7  2.7
Current 11 20  12 2.7  2.2
Alcohol
None 51 22  20 3.1  2.9
Less than seven times per week 40 18  15 2.6  2.0
7 times per week 9 22  30 2.4  2.2
Multiply by 0.0347 to convert total T concentrations from nanograms per deciliter to nanomoles per liter. Multiply by 3.47 to convert free
T concentrations from picograms per milliliter to picomoles per liter. P values are based on differences in mean values of log-transformed total
and free T within the variable categories.
a P  0.05.
b P  0.001.
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pause, there was no significant association between calcu-
lated number of years since menopause and total or free T
levels.
Combined effect of ovarian removal and estrogen use
There was no evidence of synergy between the effects of
ovarian removal and estrogen use (P value for interaction
term  0.43). Indeed, once both ovaries had been removed
or estrogen was taken, the other risk factor had no additional
impact on total or free T levels.
Discussion
Our data, obtained from women in late postmenopause
heterogeneous in age, race, reproductive history, and estro-
gen replacement, suggest that a distribution shift occurs in T
levels with advanced age. Although the mean total T levels
in our study population are half and the free T levels two
thirds of those seen in premenopausal women (13), the same
factors that affect the production of T in premenopausal
women also are influential in elderly women whose time of
menopause averaged 25 yr earlier.
Unlike dehydroepiandrosterone sulfate or IGF-I, which
demonstrate progressive declines with age (15–17), total
and free T levels did not decrease linearly in these elderly
women, even after adjusting for other confounders of the
age-T relationship. The adjusted models of total T suggest
a decrease with age until 80 yr, followed by a slight in-
crease in levels. Whether the higher T levels seen in the
TABLE 2. Total and free T levels by reproductive variables and
medications
Variable Sample%
Total T, mean  SD
(ng/dl) (n  347)
Free T, mean  SD
(pg/ml) (n  342)
Pregnancies
None 12 19  19 2.4  1.9
At least one 88 20  19 2.9  2.6
Years since
menopause
20 18 18  19 2.4  1.7
21–25 28 19  16 2.8  2.7
26–30 23 22  21 3.3  2.9
31–35 13 24  25 3.2  3.2
36 18 18  15 2.7  2.2
Hysterectomy
Unknown 4 23  28 2.6  1.6
No 53 20  20 2.9  2.7
Yes 43 20  18 2.8  2.4
Type of menopause
Unknown 4 25  30 2.6  1.6
Natural 63 20  19 2.9  2.6
Surgical 33 20  18 2.8  2.5
No. of ovaries removed
Unknown 13 24  24a 3.3  3.6b
0 63 20  19 2.8  2.1
1 8 24  21 3.5  3.7
2 16 13  12 2.4  2.4
Estrogen use
Never 54 23  20c 3.2  2.7c
Past 27 17  16 2.4  1.7
Current 19 14  18 2.5  2.9
Oral corticosteroid
use
No 97 20  19c 2.8  2.4a
Yes 3 5  5 1.6  1.3
Multiply by 0.0347 to convert total T concentrations from nano-
grams per deciliter to nanomoles per liter. Multiply by 3.47 to convert
free T concentrations from picograms per milliliter to picomoles per
liter. P values are based on differences in mean values of log-trans-
formed total and free T within the variable categories.
a P  0.01.
b P  0.05.
c P  0.001.
FIG. 1. Total T (nanograms per deciliter) vs. free T (picograms per
milliliter).




























































FIG. 2. A, Total T (nanograms per deciliter) vs. age. B, Free T (pico-
grams per milliliter) vs. age.
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oldest women are a result of survival bias or a true phys-
iological phenomenon cannot be determined in this cross-
sectional analysis. Free T levels did not differ by age in our
study. Other studies have not measured free T by dialysis
in women 65 yr or older but have shown either a U shape
or decline with age using other measures (8, 9). When we
replaced age with time since menopause, we saw no re-
lationship between this alternate time axis and total or free
T levels, consistent with findings from other studies sug-
gesting no impact of menopause on T production (8, 9, 18).
The factor with the greatest impact on T levels in these
older women was corticosteroid use. Exogenous cortico-
steroids have been shown in small studies of premeno-
pausal (19, 20) and postmenopausal (21) women to lower
T levels by decreasing both adrenal androgen production
and ovarian steroidogenesis through multiple inhibi-
tory effects on the hypothalamic-pituitary-adrenal and
hypothalamic-pituitary-ovarian axes (22). Therefore, it is
not surprising that free and total T levels were low in this
group. Our findings also suggest that if T is biologically
TABLE 3. Independent determinants of total T levels





70–74 0.74 0.55, 0.98 0.04 26% lower
75–79 0.65 0.47, 0.90 0.01 35% lower
80 0.90 0.63, 1.28 0.54 10% lower
Race 0.19
White 1.00 Reference
Black 1.20 0.92, 1.57 0.19 20% higher
BMI (kg/m2) 0.005
18.5 0.72 0.45, 1.16 0.17 28% lower
18.5–24.9 1.00 Reference
25–29.9 1.24 0.98, 1.56 0.07 24% higher
30.0 1.47 1.14, 1.89 0.003 47% higher
Ovaries removed 0.05
0, 1, or unknown 1.00 Reference
2 removed 0.77 0.59, 1.00 0.05 23% lower
Estrogen use 0.0001
Never 1.00 Reference
Past 0.85 0.67, 1.06 0.15 15% lower
Current 0.53 0.41, 0.70 0.0001 47% lower
R2  0.166645. CI, Confidence interval.
a Analysis based on log-transformed data for total T. Values are multiplicative effects on total T, generated from antilogs of adjusted effects,
reported as a fold effect, compared with reference group. Estimates are reported from a multivariate model that included age, race, BMI, ovarian
status, and estrogen use.
TABLE 4. Independent determinants of free T levels





70–74 0.93 0.76, 1.14 0.50 7% lower
75–79 1.03 0.82, 1.29 0.83 3% higher
80 1.02 0.80, 1.32 0.86 2% higher
Race 0.0001
White 1.00 Reference
Black 1.51 1.25, 1.83 0.0001 51% higher
BMI (kg/m2) 0.11
18.5 0.86 0.59, 1.24 0.41 14% lower
18.5–24.9 1.00 Reference
25–29.9 1.14 0.97, 1.34 0.11 14% higher
30.0 1.20 1.00, 1.44 0.05 20% higher
Ovaries removed 0.06
0, 1, or unknown 1.00 Reference
2 removed 0.84 0.69, 1.01 0.06 16% lower
Estrogen use 0.02
Never 1.00 Reference
Past 0.78 0.71, 0.98 0.03 22% lower
Current 0.53 0.65, 0.95 0.01 47% lower
R2  0.138638. CI, Confidence interval.
a Analysis based on log-transformed data for free T. Values are multiplicative effects on free T, generated from antilogs of adjusted effects,
reported as a fold effect, compared with reference group. Estimates are reported from a multivariate model that included age, race, BMI, ovarian
status, and estrogen use.
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relevant in older women, this would be the group that
would experience the most adverse consequences due to
their very low levels.
Women with both ovaries removed were also found to
have lower total and free T levels. This effect was specific to
the ovaries; there was no impact of hysterectomy on T levels
unless both ovaries were removed at the time of surgery. Our
finding is consistent with a study in which T levels were
determined before and after oophorectomy in 16 postmeno-
pausal women, with a 50% decline after oophorectomy (23)
and two other cross-sectional studies examining this risk
factor in late postmenopausal women (8, 9).
Current estrogen use had a similar impact on total and free
T levels in our study, suggesting that SHBG elevation did not
entirely explain the estrogen effect. Our results may reflect
an additional estrogen effect on ovarian T production via
negative feedback on LH production. Our findings concur
with studies of early postmenopausal women in which total
and calculated free T decreased with estrogen use (24, 25) but
differ from studies in which only the calculated free T de-
clined (26, 27). Our data also imply a mild effect of past
estrogen use on T levels, although other unmeasured factors
may account for this observation. Whether a protracted effect
on T production occurs from prior estrogen use requires
validation in other studies. We were unable to demonstrate
synergy or even an additive effect, between ovarian removal
and estrogen. For example, once a woman had undergone
bilateral oophorectomy, no additional effect of estrogen use
could be detected.
Race was a strong predictor of free but not total T levels,
even after adjusting for other confounding factors, including
BMI, suggesting differences in T binding between black and
white women. In more than 2000 perimenopausal women
enrolled in the Study of Women’s Health Across the Nation
(SWAN), total T and SHBG levels did not differ between
African-American and Caucasian women (28). We are un-
aware of data suggesting a mechanism for this finding, which
could also be attributable to unmeasured confounders.
Our data show a linear relationship between T levels and
BMI that is stronger for total than free T. Other studies have
shown associations between T and BMI, insulin resistance,
and the metabolic syndrome in peri- or postmenopausal
women (8, 18, 28–32). This association suggests a relation-
ship between T and insulin resistance in postmenopausal
women that is either a generalized phenomenon or sugges-
tive of polycystic ovary syndrome physiology many years
after menopause. The direct relationship between BMI and
T levels in women contrasts strikingly with that in men, in
which BMI is inversely correlated with total T levels (33).
There is considerable controversy surrounding the mea-
surement of T levels, particularly in women, and any assay
has the potential for artifact at the lowest levels (5). Our total
T levels were measured with a high-sensitivity assay opti-
mized in the female range and validated against mass spec-
trometry methods (LC-MS/MS) (14). Our free T levels were
measured via equilibrium dialysis, considered the gold stan-
dard for free T measurement (5, 34). Because of the precision
of our assays, we were able to detect the impact of different
factors that affect T levels in postmenopausal women, even
at the very low T levels present in our aged study population.
In our study, the major predictors of total and free T levels,
except race, were the same as in younger women. However,
the magnitudes of the effects of these predictors differed for
total and free T. Whether sufficient additional information is
obtained from the technically challenging equilibrium dial-
ysis assay, compared with use of total T or free T calculations
using SHBG, to merit its use clinically in late postmenopausal
women remains to be determined. Continued research on the
clinical implications of lower vs. higher total and free T levels
in older women is needed to answer this question.
The strengths of our study include its population-based
sample, which was not selected based on symptoms or re-
productive characteristics that could be related to T levels;
the richness of data collected on various reproductive and
health characteristics; and the use of highly sensitive assays.
However, several limitations should be acknowledged. First,
there is the potential for misclassification of predictor vari-
ables, especially menopause age, oophorectomy history, and
prior estrogen use due to imprecise recall of events occurring
many years previously. In the Rancho Bernardo Study, hys-
terectomy and oophorectomy status was validated by oper-
ative records in a subgroup of 228 women. They found that
96% of women who reported bilateral oophorectomy were
correct, whereas 33% of women reporting ovarian conser-
vation had bilateral oophorectomy (8). This suggests that our
estimates for T level reductions after oophorectomy likely
underestimate the true impact of hysterectomy. Second, our
analysis is cross-sectional in nature; thus, we are unable to
assess the effects of time or reproductive variables in the
same woman over time. Third, although we determined sev-
eral significant predictors of T levels in older women, the
value of r2 was less than 17% for all adjusted models. This
suggests that there were multiple unknown determinants of
T levels in this age group, including genetic factors, unac-
counted for in our models.
The clinical relevance of a specific T level is unknown. For
example, lower sexual function is unassociated with lower T
levels in women (35). The levels we observed are lower than
those seen in premenopausal women but higher than those
seen in women with pituitary disease (36) and HIV (13, 37,
38). According to the Princeton Consensus Panel on Female
Androgen Deficiency Syndrome, a working definition of fe-
male androgen insufficiency, to be used in conjunction with
symptoms, is the bottom quartile of the normal range for free
T for 20- to 40-yr-old women (1). Using this laboratory cutoff
and the data available for our assay, 62% of the women in our
study would meet this criterion. As in men, any definition of
androgen insufficiency should be associated with other clin-
ical signs or symptoms that are improved with T therapy (39).
However, if low T levels have an effect on physiological
parameters in women, then the risk-benefit ratio of bilateral
oophorectomy at the time of hysterectomy should be reeval-
uated. Furthermore, the detrimental effects of estrogen ther-
apy in late postmenopausal women, as demonstrated in the
Women’s Health Initiative (40), may not be attributable en-
tirely to the direct effects of estrogen but also partially due
to their effects in lowering T. Because estrogen administra-
tion lowers T levels, using an estrogen-alone comparison
group in estrogen-testosterone studies in postmenopausal
women with intact ovaries does not allow exclusive evalu-
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ation of T therapy. Additional research is required to clarify
the role of T in women of all ages.
There is growing evidence of improvement in some do-
mains of sexual function in response to T therapy in women
who have had oophorectomy (41–43), but data are lacking on
the effects of T supplementation in late postmenopausal
women on these and other outcomes, including muscle,
bone, and cognition (10). T therapy use in women of this age
group is untested and requires clarification of the risk to
benefit ratio, target population, and desirable T level before
such studies are conducted (10, 44, 45).
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